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Abstract
Flux balance analysis (FBA) is an increasingly useful approach for modeling the behavior of
metabolic systems. However, standard FBA modeling of genetic knockouts cannot predict
drug combination synergies observed between serial metabolic targets, even though such
synergies give rise to some of the most widely used antibiotic treatments. Here we extend
FBA modeling to simulate responses to chemical inhibitors at varying concentrations, by
diverting enzymatic flux to a waste reaction. This flux diversion yields very similar qualitative
predictions to prior methods for single target activity. However, we find very different predic-
tions for combinations, where flux diversion, which mimics the kinetics of competitive meta-
bolic inhibitors, can explain serial target synergies between metabolic enzyme inhibitors
that we confirmed in Escherichia coli cultures. FBA flux diversion opens the possibility for
more accurate genome-scale predictions of drug synergies, which can be used to suggest
treatments for infections and other diseases.
Introduction
Microbial infections are a major burden on societies, and the emergence of drug-resistant bac-
teria poses an increasing threat to human welfare. Drug combinations can overcome resistance
by creating new therapeutic avenues inaccessible to single target drugs [1–3] or eliminating
functional redundancies exhibited by robust biological networks [4]. However, although com-
binations are increasingly the standard of care for many bacterial infections [5,6] the complex-
ity of microbial biology and the vast number of possible target combinations makes finding
new effective drug combinations challenging.
Systems biology may provide a solution to this challenge [7–9], by modeling microbial sys-
tems as complex networks of interacting components. Dynamic models of microbial function
under drug treatment [10,11] can provide detailed and accurate representations of phenotypes,
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but the scale of such models is limited by the scarcity of kinetic molecular reaction rate mea-
surements. Graph-theoretic networks of metabolic interactions found in KEGG or Metacyc
[4,12,13] can address the true scale of microbial biology, but are limited to static representa-
tions with only limited relevance to drug response phenotypes.
A successful approach towards genome-scale modeling is Flux Balance Analysis (FBA) [14–
16], which utilizes reaction stoichiometry to model metabolic capabilities at steady state (Fig 1A).
By integrating the properties of metabolic networks into a single growth phenotype, FBA enables
predictions of enzymatic gene essentiality and even genetic interactions. FBA approaches have
been used to predict the nutrient-dependent metabolic phenotype of gene knockouts (Fig 1B)
[15,17], and have been successfully applied to model the combined effects of double knockouts in
microbial systems [18]. Recently, integration of proteome structure has allowed for the prediction
of the temperature dependence of metabolic reactions on a genome wide scale [19]. Several meth-
ods have also been developed to incorporate gene expression and other high throughput data to
constrain fluxes through particular reactions predicting metabolic states corresponding to specific
gene expression states; E-flux in particular has been used to predict the impact of drugs given
expression data [20–24]. Finally, incorporation of gene expression networks and protein transla-
tion processes has enabled a mechanistically detailed description of cellular trade-offs occurring
during various growth phases and nutrient limitations [25–29]. However, none of the above meth-
odologies models the effects of drug dosing. The continuous responses to varying inhibitor con-
centrations are especially critical for identifying and interpreting drug combination effects [10].
Here we have extended FBA modeling to simulate drug effects over multiple doses. We
explore new methods for simulating drug treatments with FBA, considering both direct target
flux restriction [3] and a model that diverts flux to non-productive waste pathways (Fig 1). In
flux restriction “FBA-res”, the flux through the target reaction is restricted by a variable scalar
factor (Fig 1C), while in flux-diversion “FBA-div”, we instead divert flux to a waste reservoir
(Fig 1D). The two methods yield similar results to knockout simulations for single agent effects,
but have very different predictions for combinations. Only FBA-div predicts potent antibiotic
synergies targeting metabolism.
Materials and Methods
Simulations
The Escherichia Coli iAF1260 model created by Bernhard Palsson’s group at UCSD serves as
our bacterial model in this work [30], which contains species-specific metabolic reactions,
linked together in a network by substrates and products. For our simulations, we will assume
bacterial growth on rich media with ample supplies of oxygen, glucose, ammonia, potassium,
sulphur, and all amino acids.
All drug effect simulations were performed with an R-script using the R package Sybil (Sys-
tems Biology Library for R) [31] and the genome-scale reconstruction of Escherichia Coli. The
“Ec_iAF1260_flux2”model was downloaded in xml format and added to the R workspace.
After downloading, the growth flux is calculated using the built-in optimization module “opti-
mizeProb” with the algorithm set to “fba”. The theoretical framework for FBA-res models drug
perturbations as a scalar restriction of flux through a targeted reaction. We implement FBA-res
by reducing the flux bounds by a scalar alpha for each dose of every target. This creates a new
drug-perturbed model. The drug-perturbed model is sent to optimizeProb with the algorithm
set to “fba”. Growth inhibition is calculated with the unperturbed and perturbed growth fluxes.
After each dose for combinations or single agents, we reset to the original model to implement
the next perturbation. The theoretical framework for FBA-div models drug perturbations as a
scalar diversion of flux, which depends on the magnitude of the perturbation (dose). We
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Fig 1. Simulations of inhibited FBAmetabolism. (A) Cartoon of a target enzyme “j” which acts on substrate “i” at a steady-state flux vj. Other enzymes may
compete for the same substrate, and downstream reactions will convert all products to “biomass” flux or unproductive “waste” that is degraded or exported.
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implement FBA-div by first adding waste reactions and waste metabolites to the model. Ini-
tially the waste metabolites do not belong to any reaction, and the waste reactions consume
waste metabolites irreversibly. To simulate drug effects, the amount of metabolites produced
by a targeted reaction are reduced by alpha and the remainder of mass is converted into a
waste metabolite, which is now connected to the targeted reaction. Waste reactions consume
any diverted waste metabolites. In the case of reversible reactions, two irreversible reactions are
created with different waste metabolites, and the reduction by alpha is applied to both reac-
tions. This is the drug-perturbed model. The drug-perturbed model is sent to the optimization
module “optimizeProb” with the algorithm set to “fba”. Growth inhibition is calculated with
the unperturbed and perturbed growth fluxes. After each dose for combinations or single
agents, we reset to the original model to implement the next perturbation.
Drug effects on a targeted metabolic reaction were implemented in the genome-scale model
either by limiting the target flux (FBA-res) or limiting the amount of mass converted from sub-
strate to product by diverting metabolic mass to a waste reaction (FBA-div). Inhibition values
Inhib = 1 - ftreat/fwt, where fwt and ftreat are the simulated biomass flux rates for untreated and
drug treated bacteria. In both of our model implementations the MOMA quadratic program-
ming algorithm for simulating perturbed biological networks was implemented to find the
change in biomass flux. The IC50 value for a reaction describes the amount by which reaction
flux must be reduced to inhibit growth by 50%. For FBA-res, flux is directly restricted by a sca-
lar drug concentration, and so the IC50 is the scalar that achieves a 50% growth inhibiting flux
restriction. For FBA-div, flux is diverted to a waste reaction, and so the IC50 is the value that
achieves 50% growth inhibiting flux diversion. First, a central perturbation of αcent (where
αcent = 1+[Inhibitor]/Ki and for simplicity Ki = 1) was found for each target enzyme using a
bisection search to yield half the inhibition level of a full FBA gene deletion (for enzymes show-
ing no deletion phenotype, we used α = 5,000,000 since this value reproduced synthetic lethal
interactions in [12]. Simulated response curves were then generated for each enzyme, with five
concentrations centered on this αcent using 3x dilution steps of inhibitor concentration (α-1),
covering a ~100x dynamic range (Fig 2A). For each pair of agents, we then generated dose
matrices by simulating combined inhibitors at all pairs of those concentrations (Fig 2B). Gradi-
ent or secant-based optimization could provide faster solutions, so readers may wish to explore
such methods in future applications of this approach. Complete analysis methods are provided
as S1 Dataset, which includes the metabolic network matrix, the analysis code, and all support-
ing data files. Complete simulation results are also provided in S1 Table.
Single agent effect, combination synergy score, and epistasis
We used simple metrics of single agent and combined inhibitor responses (Fig 2A), based on
maximum inhibition levels max(I) or on 50% inhibitory concentrations IC50. Comparing max(I)
values permits comparisons with standard FBA knockouts, while IC50s allow fuller use of the
dose-responsiveness of inhibitors. The maximum inhibition max(I) and 50% crossing concentra-
tion IC50 was measured for each target, and if max(I)<0.5, IC50 was set to the top concentration.
Synergy was then determined for each dose matrix using either an effect difference max(ΔI)
or “shift index” SI50, compared to the single agents (Fig 2B). The combination data IXY (blue
(B) When the target is knocked out by setting vj = 0, substrate backlog increases flow through other reactions, and increased waste rates reduce biomass. (C)
FBA-res reduces the target flux by a scalar factor α, causing a partial knockout effect. (D) For FBA-div, the reaction's efficiency is reduced by scaling its
stoichiometric coefficient sij, diverting the backlog to waste. Because this diversion prevents yet more flux from going to biomass, FBA-div yields stronger
inhibition levels than corresponding FBA-res simulations. In this illustration, both FBA-res and FBA-div reduce the target flux by the same factor alpha, but the
smaller backlog in FBA-div leads to less non-waste network flux being directed to biomass, leading to a stronger total inhibition.
doi:10.1371/journal.pone.0147651.g001
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point) are compared to the corresponding single agent response values IX,IY (green points),
and max(ΔI) = max{IXY - max(IX,IY)}, shows the Gaddum “best single agent” expectation [32].
All combination points were considered, with the largest difference across the matrix recorded
as the score. Positive max(ΔI) values correspond to synergy (more effect than the better single
agent at comparable doses). For dose shifting, the matrix diagonal (blue area) is compared to
the two single agent curves (green areas). The combination’s 50% inhibitory crossing point
along the diagonal has single agent component concentrations C50X and C50Y, which are com-
pared to the single agent 50% inhibitory concentrations IC50X and IC50Y, to calculate
SI50 = max(C50X/IC50X, C50Y/IC50Y). This SI50 indicates whether the combination shows
synergistic (SI50<1) or antagonistic (SI50>1) dose shifting, relative to the Gaddum response
surface. We also calculated a standard Loewe combination index CI50 = CX/IC50X + CY/
IC50Y, which measures synergy relative to Loewe dose additivity[33], which is used to deter-
mine whether a combination outperforms a “drug-with-itself” sham combination (CI50 = 1 for
dose-additive). All scores for simulated and experimental combinations are listed in S1 Table.
Simulated epistasis was classified (Fig 2C and 2D) based on the max(I) values for a combi-
nation and its single agents. If a combination’s max(I)< 0.05 or max(ΔI)< 0.05, we set epista-
sis to non-interaction “None”, corresponding to a Gaddum “best single agent” interaction
model. Epistasis was then set to potentiation “Pot” if single agent max(I)> = 0.5 for both
agents, synthetic lethal “SL” if max(I)< 0.5 for both agents, or partial synthetic lethal “PSL”
otherwise. To account for higher noise levels in experimental combinations, we used the same
classification scheme, except that epistasis = None was called when max(I)< 0.25 or max(ΔI)
< 0.25 for a combination. Epistasis calls are recorded in S1 Table.
Proliferation assay
To experimentally validate the predicted drug interactions, 28 drug-pairs were tested against E.
coli MG1655 (S3 Table). In order to explore the full interaction surface the drug pairs were
tested in an 8x8 well 2d drug-gradient matrix in a 96 well plate, in addition to the drug matrix
the plate also contained gradients for each of the single drugs as well as negative and positive
controls. For both the drug matrix and the single drug gradients the highest drug concentra-
tions were 4 times above the minimal inhibitory concentration (MIC). The plates were inocu-
lated with a 96 pin replicator and incubated 18–20 hours at 37°C. After incubation, OD600 was
read using a BioTek H1 plate reader. Each plate was produced in five replicates. Raw data are
presented in S4 Table, and response scores are in S1 Table.
Results
Flux balance analysis frameworks for modeling drug inhibition
Extensive networks of microbial metabolism have been constructed that link together thou-
sands of species-specific metabolic reactions mined from the literature and online databases
[34]. Simulating the behavior of microbial metabolism requires not only the stoichiometry
Fig 2. Activity and synergymeasures for each combination. (A) Inhibition of each enzyme was simulated at five α concentrations, using 3-fold dilution
intervals centered on the concentration that yielded half of the maximum simulated effect. Note that the 3x dilution steps were constant in simulated
concentration α-1, so they are not always equal on these curve plots based on α. The maximum inhibition max(I) and 50% crossing concentration IC50 was
measured for each target (IC50 = top concentration if max(I)<0.5), and each combination was simulated at all 25 concentration pairs. (B) For combinations,
we scored the maximum effect max(I) and synergy over Gaddum’s “best single agent” reference max(ΔI) = max{IXY - max(IX,IY)} across all inhibitions IXY. We
also calculated “potency shift index” from the 50% inhibition crossing concentrations (C50X,C50Y) along the matrix diagonal (blue), where SI50 = max(C50X/
IC50X,C50Y/IC50Y). Epistasis types for (C) FBA-res and (D) FBA-div simulations on three example target pairs. Interactions were classified based on the
single agent and combination effect and synergy, as either non-interacting “None”, synthetic lethality “SL” between inactive inhibitors, partial SL “PSL”
involving one active agent, or potentiation “Pot” between two active inhibitors.
doi:10.1371/journal.pone.0147651.g002
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captured by such networks, but also detailed kinetic parameters which are unknown for most
reactions–even for well-studied microbes like E. coli. FBA addresses this limitation by replacing
those parameters with linear fluxes through all the metabolic reactions, and using linear pro-
gramming to derive steady-state flux values optimized based on an objective function con-
structed from experimental abundances of nucleotides, amino acids and of anabolic
metabolites [15,16,35]. FBA models optimize steady-state production of these essential build-
ing blocks, enforcing consistency with limits imposed by the network’s connectivity, flux limits
and the conservation of mass between reactions.
FBA models have been used to successfully predict the effects of genetic knockouts [15,17]. In
FBA, under steady state, a system of j = 1. . .N reactions between i = 1. . .Mmetabolites should
satisfy ∑j sij vj = 0, where vj are the reaction velocities and sij are stoichiometric coefficients that
account for reaction affinities and connectivity. FBAmodels solve for the vj that maximize simu-
lated flux through the objective function, constrained by this mass conservation requirement and
any vj,min< vj< vj,max limits. To model gene essentiality using the standard knockout “FBA-ko”
approach, the target enzyme’s reaction rate is set to vj = 0, after which the model is re-optimized
with a linear programming algorithm to maximize the objective function (Fig 1B and S1 Fig).
Growth is represented by a biomass reaction which integrates the outputs frommany metabolic
pathways. A refinement to FBA applies “minimization of metabolic adjustment” (MOMA) [36],
which requires the re-optimized reaction coefficients to minimize their distance from the unper-
turbed values, rather than seeking the maximum objective function flux consistent with the
applied constraints. MOMA has been applied to E. coli and yeast metabolic networks and can
successfully predict phenotypic responses to single [36] and double knockout experiments [18].
Extending FBA to drug perturbations, we consider two approaches: our “FBA-res” (previously
described in Lehar et. al. 2009 [3]) directly restricts the target flux while our “FBA-div” diverts
flux to non-productive waste. FBA-res reduces the flux vj through a targeted reaction by a scalar
factor α (Fig 1C and S1 Fig). Thus, instead of FBA’s vj = 0 constraint, we set vj!vj/α and re-opti-
mize the reaction fluxes, using MOMA. FBA-div modeling scales down the target’s stoichiometric
coefficient, rather than its maximum reaction rate (Fig 1D and S1 Fig). Specifically, FBA-div
inhibits an enzyme by setting sij!sij/α, for metabolites targeted by the inhibitor, before re-opti-
mizing to the objective function. To conserve mass, we introduce transport reaction, si(N+1), with
compensating stoichiometric coefficients si(N+1) = 1-∑j sij/α that divert excess substrate to an infi-
nite waste sink. We use standard FBA linear programming to solve the optimization problem in
conjunction with our FBA-div methodology. In contrast to FBA-res, this waste diversion prevents
other enzymes from increasing their reaction rates in response to target flux restriction. This usu-
ally predicts greater biomass reductions than FBA-res for the same level of target flux inhibition.
Simulating drug epistatic interactions
To evaluate these approaches, we simulated combination effects using standard FBA-ko, FBA-
res and FBA-div, applied to the iAF1260 model of Escherichia colimetabolism [30]. To explore
mechanistic patterns, we chose 50 enzymes to cover synthetic lethal synergies and antagonisms
found using FBA-ko [12] and sample key pathways in bacterial metabolism (S2 Table). Inhibi-
tion of each target was simulated at 5 “drug” concentrations using FBA-res and FBA-div, in
each case estimating inhibition by the flux through the growth reaction in perturbed and
unperturbed states (Materials and methods and S1 Fig). We used the same methodology to
generate combination response matrices across all 25 pairings of single drug concentrations.
To score the simulation results, we used metrics of single agent and combined inhibitor
responses, based on maximum inhibition levels or on 50% inhibitory concentrations IC50 (Fig
2A and 2B), and focused our analysis on the maximum effect max(I) and synergy score max
Simulating Serial-Target Antibacterial Drug Synergies Using FBA
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(ΔI). We also classified simulated interactions into four epistasis types, based on the dose
matrix response shapes (Fig 2C and 2D). These analyses were performed for all 1225 possible
pairwise combinations of our 50 targets (S1 Table).
The single agent responses were very similar between methodologies, but combinations dif-
fered greatly (Fig 3 and S2–S4 Figs). Both FBA-res and FBA-div single agent activities were
consistent with FBA knockouts (R~1, Fig 4). Moreover, even the IC50 concentrations showed
a strong quantitative correlation (R = 0.98, Fig 5). For combinations (Fig 4B), all three
approaches mostly generated non-interacting pairs, with max(I) reflecting the more effective
single agents, and no epistasis. However, there is a clear increase in the number and variety of
interactions between FBA-ko, FBA-res, and FBA-div. While FBA-ko synergies were restricted
to synthetic lethal (SL) epistasis, some partial synthetic lethal (PSL) appeared in FBA-res, and a
large number of potentiation (Pot) synergies were added with FBA-div.
Arranging the results by target pathway reveals informative patterns (Fig 3 and S2–S4 Figs).
First, we located our iAF1260 targets on the iJR904 [37] pathway maps, and then assigned gene
identities with reference to KEGG [34]. No visual maps were published for the iAF model that
we used, so we used the iJR maps to construct our visual displays. Pathways were then repre-
sented using concise descriptors listed in S2 Table. All three simulation approaches show active
single agents clustered in pathways essential for E. coli growth in rich media (glycolysis, citrate
cycle, folate and murein biosynthesis, and certain amino acid pathways), and the responses for
any particular enzyme are more or less uniform within each such pathway.
Fig 3. Comparing FBA-ko and FBA-div interactions acrossmetabolic pathways. Simulated interactions for (A) FBA-ko and (B) for FBA-div, in selected
metabolic pathways. More complete simulation results are shown elsewhere (S2–S4 Figs). Each symbol represents the simulated response to inhibiting a
single or pair of targets (see Fig 2), with enzymes organized by pathway and metabolic reaction order in the iAF1260 model. Symbol shape shows the type of
epistasis (synthetic lethal “SL”, partial synthetic lethal “PSL”, potentiation “Pot”, or non-interaction “None”), size shows the effect max(I), and color shows the
synergy max(ΔI) between two targets (same scale as Fig 2). Single agents are shown along the bottom and right edges. The triangles for PSL epistasis point
toward the inactive agent in the pairing. Single enzyme effects are very similar between FBA-ko and FBA-div, but interactions are very different. Most notably,
strong Pot synergies are observed between serial targets in the same pathway under FBA-div (A), which are not predicted by FBA-ko (B) or FBA-res (S4 Fig).
doi:10.1371/journal.pone.0147651.g003
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Fig 4. Comparing single agent and combination effects betweenmethods. (A) Simulated single agent inhibitions are very consistent between
methodologies. Across the 50 simulated inhibitors, both FBA-res and FBA-div methodologies yielded very similar max(I) scores to those obtained from
standard FBA-ko. Data were randomly dithered by ~0.03 in both directions to visually separate overlapping points. (B) Simulated combination effects,
however, showmany deviations in max(ΔI) from FBA-ko, and substantial differences in epistasis types. Across all 1225 simulated pairs, FBA-ko yielded
mostly None, with a few SL (2%). Simulating with FBA-res converted a few of the None to PSL (5%), and FBA-div reproduced all the FBA-res synergies and
converted another 16% from None to Pot. Data were randomly dithered by ~0.03 to separate overlapping points.
doi:10.1371/journal.pone.0147651.g004
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Combination effects within pathways and interactions across pathways were mostly consis-
tent across targets in each pathway even though they vary substantially between the different
simulation methodologies. Specifically, FBA-ko (Fig 3 and S2 Fig) generated a small number of
SL interactions, all of which are between individually inactive alternative reactions that are con-
nected by a shared downstream output. Examples include TKT2 with other Energy/pentose
enzymes, PPS with other Energy/glycolysis enzymes, and multiple isozyme pairs (GLUDy+-
GLUSy, TRPS1+TRPS3, GARFT+GART, DHORD2+DHORD5). There are also weaker inter-
actions between PGL in Energy/pentose and the Energy/glycolysis enzymes, as well as between
the glycolysis and Amino/SerGly pathways. Inhibiting with FBA-res (S3 Fig) reproduced all of
these effects, but also added some PSL synergies involving one responsive target, either between
closely connected enzyme pairs (eg, GLUDy+GLNS or between the Energy/pentose and
Energy/citrate pathways). Finally, FBA-div simulations (Fig 3 and S4 Fig) recapitulated all of
the FBA-ko and FBA-res effects, with a large number of additional Pot synergies. Generally,
Pot occurred between pathways with active targets, especially between serial targets in the same
pathway. Interestingly, the level of Pot synergy varied, with the strongest between serial targets
in the same pathway (eg, in folate, murein, and amino-Lys). Cases where specific enzymes in a
pathway stand out can be explained. For example in murein biosynthesis, there is strong FBA-
res synergy between ALAR in amino-Ala with MCT1App and MPTG but the synergy is much
weaker with UAGCVT (Fig 3 and S4 Fig). This can be understood as an extension of serial tar-
get synergy, because multiple alanine moieties dependent upon ALAR are added by MCT1App
to its substrate, but below UAGCVT in the pathway. Another example is the especially strong
interaction of SDPTA in amino/Lys with targets in Energy/citrate. A by-product of SDPTA is
alpha-ketoglutarate (akg), a key metabolite in the citrate cycle.
Fig 5. Comparing IC50 potency and SI50 synergy scores between simulation methods. Simulated single agent inhibition potencies (as–logIC50) are
very consistent between methodologies, though FBA-div responses are consistently more potent. Data were randomly dithered by ~0.03 in both directions to
visually separate overlapping points. (B) Combination synergy, as measured by–logSI50, also is very consistent for non-interactions and synthetic lethalities,
again with stronger synergies in FBA-div. Data were randomly dithered by ~0.03 in both directions to visually separate overlapping points.
doi:10.1371/journal.pone.0147651.g005
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Diverted flux FBA predicts clinical drug synergies
To test how well each of the simulation methodologies models inhibited bacterial metabolism,
we selected 28 combinations for experimental testing. Combinations were chosen to represent
known synergistic and non-synergistic combinations, using compounds that sample different
mechanisms of action across the metabolic network. The set includes cell wall metabolism
inhibitors ampicillin, aztreonam and fosfomycin, folate synthesis inhibitors sulfamethoxazole
and trimethoprim and metabolic inhibitors of central metabolic enzymes. The effect of each
combination was tested in E. coli cultures using an 8x8 drug concentration-gradient matrix,
with twofold dilutions between each step. Each top concentration was selected to capture pub-
lished in-vitro E. coli responses, and combinations were tested at all possible pairs of each
drug’s concentration series (S3 Table). Results are reported in S4 Table, with combination
response matrices displayed in S5 Fig. Calculated response and synergy scores are integrated
with the model scores (S1 Table).
Given the variety of pharmacodynamic effects that influence single agent potencies, we did
not expect and also did not find strong agreement between the simulated and experimentally
observed single agent max(I) or IC50 values (S1 Table). Aside from the clinical antibiotics,
there are very few well characterized probes with selective activity on single metabolic targets,
so it is not surprising that half of the compounds showed no activity against E. coli proliferation
(S1 Table). The antibiotics showed some agreement with the FBA simulations in terms of Max
(I) and IC50, but only in a qualitative sense.
For combinations, however, flux-diverted FBA was able to model the strong antibiotic syn-
ergies that target serial enzymes within a pathway (Fig 6A). FBA-div predicts the large potency
shifts seen for both Sulfx+Trimp and Ampcl+Aztrm, while FBA-res and FBA-ko do not (Fig
6B and S1 Table). The experiments also found a number of moderate synergies (Fig 7), most of
which involve inhibitors of targets just upstream of the same two pathways (eg, Ampcl or
Aztrm combined with Fosfm or Cyser). Only a hint of the antibiotic synergy is detected for
those probes, however, most likely due to less-specific enzyme targeting. Combination effects
were absent, as expected, for those probes showing no single agent activity and thus not likely
to have any relevant activity on the ascribed target. Finally, there was one experimental antago-
nism (Ampcl+Sulfx), that was not predicted by any of the FBA methods. Overall, comparing
synergy scores (Fig 7), FBA-res and FBA-ko synergy scores shows no consistency with the
experimental results, while the FBA-div simulations yield significant positive correlations
(R ~ 0.44, p< 0.01) for max(ΔI). Accordingly, FBA-div represents the most accurate computa-
tional predictor of serial target anti-metabolic synergies.
Discussion
While FBA methodologies have shown great potential for rationalizing metabolic engineering
efforts and identifying synthetic lethal genetic dependencies, traditional FBA knockout simula-
tions fail to predict the most useful antibiotic synergies that target metabolism. As drug combi-
nation therapies gain importance for antibiotic treatment, more accurate large-scale prediction
methods are sorely in demand. Here we show that extending FBA simulation using flux diver-
sion can accurately model the strong dose-dependent synergies observed between inhibitors of
bacterial metabolism.
The FBA-div methodology outperforms both FBA-res and standard knockout FBA for
predicting experimental combination effects, especially for one of the most important antibac-
terial combinations that target metabolism. Prior approaches for simulating drug epistasis
completely missed synergies like sulfamethoxazole and trimethoprim, because knockout and
restriction-based approaches find no interactions between serial targets in a pathway. In
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Fig 6. Experimental confirmation of simulated combination effects. (A) Known anti-metabolism drug synergies. Locating the iAF1260 model enzymes in
the KEGG E. coli MG1655 pathway maps, sulfamethoxazole + trimethoprim inhibits folC+folA in folate biosynthesis, while aztreonam + ampicillin targets
mrcB+pbpC in murein synthesis. We tested both combinations using an E. coli proliferation assay. (B) Response surfaces for the two known antibiotic
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contrast, FBA-div predicts strong synergies from targeting sequential targets in the same path-
way, similar to what has been found for competitive inhibition of serial targets with negative
feedback in kinetic simulations [10]. While this is not the usual expectation from paired knock-
out analyses [18] it is consistent with strong antibiotic synergies being used in the clinic.
Among our 28 tested combinations, the correlation between FBA-div and experimental syn-
ergy scores is modest (R ~ 0.442), due to the scarcity of selective metabolic inhibitors. However,
with metabolism increasingly a focus of drug development, especially for combinations, FBA-
div simulations could help discover and prioritize drug targets in multiple disease areas.
Broader patterns of synergy across pathways (e.g. Fig 3 and S4 Fig) can also provide key
insights into the functional connections that are most relevant to the system under study
[10,18]. It is notable that there are consistent patterns of single agent activity and combination
epistasis within a pathway, and again consistent patterns between targets across pathways, con-
firming target connection topology as a major determinant of simulated combination effects
[10,18]. This also provides the possibility of validating chemical inhibitor targets by comparing
their synergy profiles to those with known targets [10]. All three methods discussed here find
strong synthetic lethality between isozymes of essential reactions, and weaker interactions
between alternative essential pathways. However, FBA-div provides by far the richest source of
predicted synergies. For example, the citrate cycle synergizes with Lysine metabolism, but
exceptionally strongly with SDPTA, revealing a direct connection through that enzyme’s by-
combinations match the FBA-div simulations more closely than FBA-res. Although the models yield similar target inhibition levels (though requiring larger α
for FBA-res), only FBA-div predicts the observed Pot synergy.
doi:10.1371/journal.pone.0147651.g006
Fig 7. Experimental confirmation of simulated combination effects.We tested 28 combinations of metabolic inhibitors using an E. coli proliferation
assay. Synergy score comparison for all combinations, where shape/color shows experimental interaction class, and open symbols indicate epistasis type.
We find no agreement (R~0) between the experimentally determined drug interactions and FBA-res. However, experimental and FBA-div synergy are
correlated (R~0.44). In addition to the antibiotic combinations, weaker synergy is predicted and observed for other interactions between murein synthesis
inhibitors and targets further upstream.
doi:10.1371/journal.pone.0147651.g007
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product alpha-ketoglutarate. Similarly, other connections with amino acid metabolism are
revealed for the murein and folate biosynthesis pathways.
Differences between the FBA-res and FBA-div methodologies may be understood in terms
of standard Michaelis-Menten (MM) modeling for drug-inhibited enzymes. In MM kinetics,
the reaction flux v = VMS/(S+KM), where S is the input substrate’s concentration, KM is the
reaction affinity, and VM is the maximum reaction rate. In FBA-res, a scalar reduction in v by
α corresponds to a perturbed VM = VM/α, while KM = KM, since the stoichiometric parame-
ters sij that account for reaction affinities are unchanged. This is the behavior of non-competi-
tive inhibitors in MM kinetics with α = (1+[drug]/KD). By contrast, in FBA-div, scaling down
the reaction affinity corresponds to KM = KM/α, this time leaving VM = VM constant, similar
to competitive inhibitors. These scaling behaviors are consistent with combination effects seen
in kinetic pathway simulations [10], where competitive inhibition of serial targets with negative
feedback yielded strong serial-target synergies that were absent in simulations of non-competi-
tive or uncompetitive MM reactions. Thus, FBA-div more closely mimics the inhibitory kinet-
ics of metabolic inhibitors used as antibiotic drugs.
From a biology perspective, FBA-div can explain serial target synergies through the build-
up of metabolite concentrations. The waste stream in FBA-div can be thought of as represent-
ing passive regulation that limits substrate concentrations by degradation or export from the
system. Simulating with FBA-res assumes that when a drug inhibits a reaction, accumulated
mass will slow down the upstream reaction thermodynamically, or induce a gene expression
cascade that causes upstream reactions to slow down to the inhibited level. By contrast, FBA-
div assumes that upstream reactions cannot sense or adjust to an inhibited downstream reac-
tion on the time scale of the drug inhibition, and substrate is wasted, creating less biomass over
time. Also, diverting excess flux to waste mimics processes similar to the phenomenon of meta-
bolic resistance [25,38] which has been experimentally shown to result from upstream sub-
strate accumulation. Such mechanisms have been proposed to explain how microbes keep
substrate concentrations within feasible ranges, and FBA models have indeed been augmented
with explicit constraints on metabolite and Gibbs free energy levels to more accurately predict
global flux distributions [39]. Put in simpler terms, FBA-res cannot predict serial target syner-
gies because mass conservation during optimization requires any flux restriction to apply
throughout a serial pathway, forcing the combined effect to match that of the most effective
inhibitor. In FBA-div, however, inhibition diverts intermediate reaction flux to waste, yielding
greater biomass reductions.
The FBA-div approach can be extended to metabolic models of pathogens, such as tubercu-
losis [40], plasmodium [41], and the ESKAPE pathogens [42]. As more FBA models become
available for pathogens, combination effects within the current space of drugs and drug-like
small molecules could be simulated, and new therapies could be rapidly tested against drug-
resistant strains. Indeed, FBA-div for human metabolism is increasingly conceivable as mam-
malian FBA models [43] become more established. Our FBA-div perturbation approach could
also be used with simulation methodologies that extend FBA to transcriptional regulation
using ChIP-Seq and gene expression information [44], enabling yet more realistic simulations
of drug effects in biological systems. Finally, flux diversion may also more accurately predict
synergies between 3 or more drugs [4,13,45]. These extensions would also enable useful syn-
ergy predictions for drug combinations targeting mammalian metabolism.
Experimental work on drug combinations can be resource intensive, especially for patho-
gens which require a BSL 3 environment, or when large combinatorial spaces are comprehen-
sively sampled. Thus, computational tools that can explore large-scale models to prioritize
such resource-intensive work could significantly accelerate drug discovery research. Because it
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can accurately predict a great variety of drug synergies, FBA-div has the potential to make a
major impact on these therapeutic challenges.
Supporting Information
S1 Table. Complete simulation results.
(XLSX)
S2 Table. Metabolic pathway descriptors.
(XLSX)
S3 Table. Drugs used in the E. coli screen.
(XLSX)
S4 Table. Dose-response readings from the E. coli screen.
(XLSX)
S1 Fig. Simulation methodology. Calculation steps used for the three methodologies com-
pared in this work (see Methods).
(PDF)
S2 Fig. Mechanistic patterns in FBA-ko simulated inhibitor combinations. Each symbol
represents the simulated FBA-ko response to inhibiting a single or pair of targets (see Fig 2),
with enzymes organized by pathway and metabolic reaction order in the iAF1260 model. Sym-
bol shape shows the type of interaction (synthetic lethal “SL”, partial synthetic lethal “PSL”,
potentiation “Pot”, or non-interaction “None”), size shows the effect max(I), and color shows
the synergy max(ΔI) between two targets. The only strong interactions found are SL between
“interchangeable” enzymes along alternative paths to a common endpoint, and there are no
synergies between two singly essential enzymes.
(PDF)
S3 Fig. Mechanistic patterns in FBA-res simulated inhibitor combinations. Each symbol
represents the simulated FBA-res response to inhibiting a single or pair of targets (see Fig 2),
with enzymes organized by pathway and metabolic reaction order in the iAF1260 model. Sym-
bol shape shows the type of interaction (synthetic lethal “SL”, partial synthetic lethal “PSL”,
potentiation “Pot”, or non-interaction “None”), size shows the effect max(I), and color shows
the synergy max(ΔI) between two targets. The triangles for PSL epistasis point toward the inac-
tive agent in the pairing. Single enzyme effects are very similar to those for FBA-ko. Interac-
tions are also similar to FBA-ko, except that there are some PSL involving one singly essential
enzyme.
(PDF)
S4 Fig. Mechanistic patterns in FBA-div simulated inhibitor combinations. Each symbol
represents the simulated FBA-div response to inhibiting a single or pair of targets (see Fig 2),
with enzymes organized by pathway and metabolic reaction order in the iAF1260 model. Symbol
shape shows the type of epistasis (synthetic lethal “SL”, partial synthetic lethal “PSL”, potentiation
“Pot”, or non-interaction “None”), size shows the effect max(I), and color shows the synergy
max(ΔI) between two targets (same scale as Fig 2). Single agents are shown along the bottom and
right edges. The triangles for PSL epistasis point toward the inactive agent in the pairing. Single
enzyme effects are very similar to those for FBA-ko and FBA-res, but new patterns emerge for
interactions. In particular, the FBA-div simulations yield strong potentiation synergies between
serial targets in the same pathway that are not found for FBA-res or FBA-ko.
(PDF)
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S5 Fig. Experimental dose response matrices. Experimentally measured drug-drug dose
response matrices, ordered by total activity. The effects range from potentiation-like synergies
(eg, Sulfx+Trimp), through non-interacting pairs (eg, Nfurz+Trimp), to antagonisms (eg,
Ampcl+Sulfx). There were also inactive single agents such as Dfrox and Tcarb for which inter-
actions could not be accurately determined. Synergy scores were calculated and compared to
the simulated dose-response matrices.
(PDF)
S1 Dataset. Complete analysis methods.
(ZIP)
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